Oxular Limited, a clinical-stage ophthalmic company developing targeted treatments for retinal disorders, appointed Mark Gaffney chief executive officer and member of the board of directors. Gaffney succeeds Thomas Cavanagh, who has transitioned from his role as CEO to pursue other opportunities. Gaffney brings over 20 years of biotech leadership experience to Oxular. He previously served as chief business officer and chief operating officer at Vedere Bio, a private ophthalmic-focused gene th...